Dr. Daniel J. Haraf on a Less Toxic Treatment for Patients With Head and Neck Cancer
Haraf says historically, medical professionals have treated patients with radiation therapy "from their eyebrows to their collarbones." This approach, while effective, has resulted in an abundance of toxicities.
Daniel J. Haraf, MD, professor of Radiation & Cellular Oncology, medical Director, Radiation Oncology, The University of Chicago Medicine, discusses a more focused approach to radiation therapy in head and neck cancer. Haraf says historically, medical professionals have treated patients with radiation therapy "from their eyebrows to their collarbones." This approach, while effective, has resulted in an abundance of toxicities.
Haraf said a recent study shows that an approach of induction chemotherapy utilized in 100 patients, without any elective nodal radiation, resulted in a positive response for 99 of the 100 patients. Haraf said these results are "practice changing" and could result in confined radiotherapy with less toxicities.
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More
Neoadjuvant Pembro Plus Chemo Shows EFS Benefit at 5-Years in TNBC
November 13th 2023In an interview with Targeted Oncology, Peter Schmid, FRCP, MD, PhD, discussed the implication of findings from the KEYNOTE-522 trial of the addition of pembrolizumab to neoadjuvant chemotherapy in patients with high-risk triple-negative breast cancer.
Read More
